UBS Group
DMRA

UBS Group’s Damora Therapeutics DMRA Stock Holding History

UBS Group’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Buy
840,292
+679,877
+424% +$16.5M ﹤0.01% 2592
2026
Q1 		$4.15M Buy
160,415
+154,026
+2,411% +$3.96M ﹤0.01% 4263
2025
Q4 		$147K Buy
6,389
+6,330
+10,729% +$110K ﹤0.01% 6730
2025
Q3 		$220 Sell
59
-2,254
-97% -$7.63K ﹤0.01% 9800
2025
Q2 		$7.89K Buy
2,313
+2,028
+712% +$6K ﹤0.01% 8994
2025
Q1 		$883 Sell
285
-12,182
-98% -$57.4K ﹤0.01% 9630
2024
Q4 		$58K Buy
12,467
+7,368
+144% +$48.2K ﹤0.01% 7208
2024
Q3 		$62K Buy
+5,099
New +$66.5K ﹤0.01% 6681
2024
Q1 		– Sell
-171
Closed -$3.08K – 9581
2023
Q4 		$3.08K Sell
171
-113
-40% -$1.74K ﹤0.01% 8009
2023
Q3 		$5.1K Buy
+284
New +$11.2K ﹤0.01% 7391
2023
Q2 		– Sell
-99
Closed -$4.94K – 9172
2023
Q1 		$4.94K Buy
+99
New +$5.22K ﹤0.01% 8114
2022
Q4 		– Sell
-164
Closed -$8K – 10866
2022
Q3 		$8K Buy
+164
New +$8.32K ﹤0.01% 8713
2022
Q2 		– Sell
-100
Closed -$5K – 10545
2022
Q1 		$5K Sell
100
-170
-63% -$9.55K ﹤0.01% 9125
2021
Q4 		$20K Buy
+270
New +$21.2K ﹤0.01% 7838
2021
Q3 		– Sell
-313
Closed -$40K – 9743
2021
Q2 		$40K Buy
+313
New +$42.6K ﹤0.01% 6631

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

UBS Group's DMRA Position: Q2 2026 in Review

UBS Group increased its Damora Therapeutics (DMRA) stake by 424% in Q2 2026, buying an estimated $16.5M and bringing the position to 840,292 shares worth $21.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2592.

UBS Group first reported a position in DMRA in Q2 2021 and has held it in 15 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • UBS Group held 840,292 shares of Damora Therapeutics worth $21.9M as of Q2 2026.
  • UBS Group bought 679,877 Damora Therapeutics shares in Q2 2026, an estimated $16.5M.
  • Damora Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2592 holding.
  • UBS Group first reported a position in Damora Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.